Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 6/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214723 | 0.90 | PIK3CA (0.45) | ERN1MTORPIK3R1PIK3CA | |
| SCHEMBL2212206 | 0.82 | ERN1 (0.50) | ERN1CNR2MTORPIK3R1PIK3CA | |
| SCHEMBL2217996 | 0.80 | GAK (0.42) | PIK3CA | |
| SCHEMBL2215416 | 0.80 | GAK (0.52) | PIK3CA | |
| SCHEMBL2217666 | 0.79 | GAK (0.37) | PIK3CAAOC3 | |
| SCHEMBL2216042 | 0.79 | GAK (0.41) | ERN1MTORPIK3R1PIK3CAAOC3 | |
| SCHEMBL2212992 | 0.78 | ERN1 (0.44) | ERN1CYP11B2MTORPIK3R1PIK3CA | |
| SCHEMBL2218016 | 0.78 | GAK (0.39) | AOC3MAP4K1 | |
| SCHEMBL2215363 | 0.78 | LRRK2 (0.40) | ERN1CYP11B2PIK3R1PIK3CAAOC3 | |
| SCHEMBL2212554 | 0.77 | ERN1 (0.41) | ERN1MTORPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | ASTRAZENECA R&D (SE) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178064-A1 | SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL | TBCA, TUBA1A, BROX | ERN1 2259/4885CNR2 3504/4885CYP11B2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.